<p>近年來，<strong>諾和諾德</strong>（NVO 6.07%）和 <strong>禮來</strong>（LLY 0.49%）是最熱門的兩隻醫療保健股票。前者在過去五年中上漲了 400%，而後者上漲了 67%。然而，如果不是今年諾和諾德的價值大幅下跌，其漲幅將會更為顯著。</p>
<p>但這些股票仍然看起來被低估了。雖然許多投資者可能正在重新評估這兩家 GLP-1 藥物製造商未來的增長潛力，但它們似乎都被低估了。如果你還沒有投資這兩家公司，以下是你可能考慮投資的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzMzMjYvYS1kb2N0b3ItdXNpbmctYS1zY2FsZS10by1tZWFzdXJlLWEtcGVyc29ucy13ZWlnaHQuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzMzMjYvYS1kb2N0b3ItdXNpbmctYS1zY2FsZS10by1tZWFzdXJlLWEtcGVyc29ucy13ZWlnaHQuanBnJnc9NzAw"/></p>
<p>圖片來源：Getty Images。</p>
<h2>GLP-1 減肥藥物可能即將獲得覆蓋</h2>
<p>GLP-1 減肥藥物有助於抑制食慾，從而幫助人們通過更快感到飽腹來減輕體重。許多製藥公司正在競相開發 GLP-1 減肥治療，這可能是未來多年該行業最熱門的增長機會之一。</p>
<p>然而，禮來和諾和諾德具有優勢，因為它們已經在市場上擁有獲批的治療方案：禮來有 Zepbound，諾和諾德有 Wegovy。但消費者在考慮使用這些藥物時，最大的顧慮無疑是它們的價格。例如，Zepbound 的 28 天供應的標價超過 1000 美元，而 Wegovy 則超過 1300 美元。</p>
<p>據報道，特朗普政府正在考慮可能將 GLP-1 減肥治療納入醫療保險和醫療補助。如果那樣的話，這可能成為這些公司的巨大增長催化劑。雖然這些藥物可能成本高昂，但考慮到減肥帶來的整體健康改善，它們可能會減輕整個醫療保健行業的一些負擔。而且 GLP-1 藥物的好處正在逐漸顯現。</p>
<p>例如，Zepbound 去年被批准作為治療阻塞性睡眠呼吸暫停的藥物。監管機構還批准了 Wegovy，以幫助降低肥胖或超重成年人嚴重心臟問題的風險。Wegovy 的活性成分 Semaglutide 也可能在治療物質濫用障礙方面有效。</p>
<h2>這兩隻股票還有更大的增長空間</h2>
<p>這兩家公司近年來表現良好。令人興奮的是，隨着研究人員發現這些 GLP-1 藥物的更多適應症，這可能會導致更多的應用和使用案例，從而帶來更強勁的增長率。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/faff79f8f685762e63af6f0e31da6715.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/faff79f8f685762e63af6f0e31da6715.png"/></p>
<p>LLY 收入（季度同比增長）數據來自 YCharts。</p>
<p>諾和諾德的增長率今年有所下降，但未來還有更多的增長潛力。根據 Grand View Research 的數據，去年全球 GLP-1 減肥藥物市場價值為 140 億美元，預計到本世紀末將增長到 490 億美元。諾和諾德和禮來都處於良好的位置，可以從這些機會中受益。</p>
<h2>這兩隻股票看起來都是長期投資的好選擇</h2>
<p>許多投資者今年已經放棄了諾和諾德——截至 2025 年，其股價下跌了約 35%——但這可能是一個代價高昂的錯誤，因為它仍然擁有巨大的增長機會。其藥物的複合版本影響了銷售，但美國政府正在對此進行打擊。如果它為 GLP-1 減肥藥物提供覆蓋，這隻前景看好的醫療保健股票可能會再次起飛。以僅 14 倍的市盈率，今天購買的諾和諾德股票在長期內可能會被證明是一個超值交易。</p>
<p>禮來今年下跌了 3%，雖然它沒有像諾和諾德那樣自由下跌，但看起來也可能是一個被低估的買入機會。該股票的市盈率接近 50 倍，但未來的增長和更大的利潤率可能會在未來幾年顯著降低這一倍數。</p>

諾和諾德公司

禮來

<p>諾和諾德和禮來被認為是被低估的股票，儘管過去的漲幅顯著，諾和諾德在五年內上漲了 400%，而禮來上漲了 67%。這兩家公司都已獲得 GLP-1 減肥藥的批准，如果被醫療保險和醫療補助覆蓋，需求可能會增加。預計到 2030 年，GLP-1 市場將從 140 億美元增長到 490 億美元。儘管近期有所下跌，這兩隻股票仍被視為強勁的長期投資，諾和諾德的市盈率僅為 14，而禮來的市盈率為 50，暗示未來增長的潛力</p>

<p>Two of the hottest healthcare stocks in recent years have been <strong>Novo Nordisk</strong>(NVO 6.07%) and <strong>Eli Lilly</strong>(LLY 0.49%). The former has risen by 400% in the past five years, while the latter is up 67%. If not for the steep sell-off in Novo Nordisk's value this year, however, its gains would be far more significant.</p>
<div class="lb-trans"><p>近年來，<strong>諾和諾德</strong>（NVO 6.07%）和 <strong>禮來</strong>（LLY 0.49%）是最熱門的兩隻醫療保健股票。前者在過去五年中上漲了 400%，而後者上漲了 67%。然而，如果不是今年諾和諾德的價值大幅下跌，其漲幅將會更為顯著。</p>
</div><p>But these stocks still look underrated. While many investors may be reevaluating how much growth may be ahead for these two GLP-1 drugmakers, both seem to be underestimated. If you haven't invested in either of these companies yet, here's why you may want to consider doing so.</p>
<div class="lb-trans"><p>但這些股票仍然看起來被低估了。雖然許多投資者可能正在重新評估這兩家 GLP-1 藥物製造商未來的增長潛力，但它們似乎都被低估了。如果你還沒有投資這兩家公司，以下是你可能考慮投資的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzMzMjYvYS1kb2N0b3ItdXNpbmctYS1zY2FsZS10by1tZWFzdXJlLWEtcGVyc29ucy13ZWlnaHQuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F833326%2Fa-doctor-using-a-scale-to-measure-a-persons-weight.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>Coverage could be coming for GLP-1 weight loss drugs</h2>
<div class="lb-trans"><h2>GLP-1 減肥藥物可能即將獲得覆蓋</h2>
</div><p>GLP-1 weight loss drugs help to curb appetite, which, in turn, helps people to lose weight by feeling fuller sooner. Many pharma companies are racing to develop GLP-1 weight loss treatments, in what could be one of the hottest growth opportunities in the sector for many years to come.</p>
<div class="lb-trans"><p>GLP-1 減肥藥物有助於抑制食慾，從而幫助人們通過更快感到飽腹來減輕體重。許多製藥公司正在競相開發 GLP-1 減肥治療，這可能是未來多年該行業最熱門的增長機會之一。</p>
</div><p>Eli Lilly and Novo Nordisk have an advantage, however, as they already have approved treatments on the market: Lilly has Zepbound and Novo Nordisk has Wegovy. But arguably the biggest reason consumers think twice about taking them is their prices. Zepbound, for example, has a list price of over $1,000 for a 28-day supply, while Wegovy is more than $1,300.</p>
<div class="lb-trans"><p>然而，禮來和諾和諾德具有優勢，因為它們已經在市場上擁有獲批的治療方案：禮來有 Zepbound，諾和諾德有 Wegovy。但消費者在考慮使用這些藥物時，最大的顧慮無疑是它們的價格。例如，Zepbound 的 28 天供應的標價超過 1000 美元，而 Wegovy 則超過 1300 美元。</p>
</div><p>Reportedly, however, the Trump administration is looking at possibly covering GLP-1 weight loss treatments under Medicare and Medicaid. If that happens, it could become a huge growth catalyst for these companies. While the medications can be costly, given the overall health improvements that can come with weight loss, they could alleviate some of the burden on the healthcare sector as a whole. And GLP-1 drugs are turning out to have wide-ranging benefits.</p>
<div class="lb-trans"><p>據報道，特朗普政府正在考慮可能將 GLP-1 減肥治療納入醫療保險和醫療補助。如果那樣的話，這可能成為這些公司的巨大增長催化劑。雖然這些藥物可能成本高昂，但考慮到減肥帶來的整體健康改善，它們可能會減輕整個醫療保健行業的一些負擔。而且 GLP-1 藥物的好處正在逐漸顯現。</p>
</div><p>Zepbound, for instance, was approved last year as a treatment for obstructive sleep apnea. And regulators approved Wegovy to help reduce the risk of serious heart problems in obese or overweight adults. Semaglutide, the active ingredient in Wegovy, also may be effective in treating substance abuse disorders.</p>
<div class="lb-trans"><p>例如，Zepbound 去年被批准作為治療阻塞性睡眠呼吸暫停的藥物。監管機構還批准了 Wegovy，以幫助降低肥胖或超重成年人嚴重心臟問題的風險。Wegovy 的活性成分 Semaglutide 也可能在治療物質濫用障礙方面有效。</p>
</div><h2>Much more growth out there for these two stocks</h2>
<div class="lb-trans"><h2>這兩隻股票還有更大的增長空間</h2>
</div><p>Both companies have been doing well in recent years. The exciting thing is that as researchers discover more indications for these GLP-1 drugs, it could lead to more applications and use cases, which would result in even stronger growth rates.</p>
<div class="lb-trans"><p>這兩家公司近年來表現良好。令人興奮的是，隨着研究人員發現這些 GLP-1 藥物的更多適應症，這可能會導致更多的應用和使用案例，從而帶來更強勁的增長率。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/faff79f8f685762e63af6f0e31da6715.png" alt="" original-src="https://media.ycharts.com/charts/faff79f8f685762e63af6f0e31da6715.png"/></p>
<p>LLY Revenue (Quarterly YoY Growth) data by YCharts.</p>
<div class="lb-trans"><p>LLY 收入（季度同比增長）數據來自 YCharts。</p>
</div><p>Novo Nordisk's growth rate has declined this year, but there's much more growth on the horizon. Last year, the global GLP-1 weight loss drug market was worth $14 billion, and is expected to triple to $49 billion by the end of the decade, according to Grand View Research. Both Novo Nordisk and Eli Lilly look to be in excellent positions to benefit from these opportunities.</p>
<div class="lb-trans"><p>諾和諾德的增長率今年有所下降，但未來還有更多的增長潛力。根據 Grand View Research 的數據，去年全球 GLP-1 減肥藥物市場價值為 140 億美元，預計到本世紀末將增長到 490 億美元。諾和諾德和禮來都處於良好的位置，可以從這些機會中受益。</p>
</div><h2>Both stocks look like great buys for the long haul</h2>
<div class="lb-trans"><h2>這兩隻股票看起來都是長期投資的好選擇</h2>
</div><p>Many investors have given up on Novo Nordisk this year -- it's down around 35% thus far in 2025 -- but that could be a costly mistake, given that it still has tremendous growth opportunities ahead. Compounded versions of its drugs have affected sales, but the U.S. government is cracking down on that. And if it offers coverage for GLP-1 weight loss drugs, the promising healthcare stock could be off to the races again. At a price-to-earnings multiple of just 14, Novo Nordisk shares bought today may prove to be a steal of a deal in the long run.</p>
<div class="lb-trans"><p>許多投資者今年已經放棄了諾和諾德——截至 2025 年，其股價下跌了約 35%——但這可能是一個代價高昂的錯誤，因為它仍然擁有巨大的增長機會。其藥物的複合版本影響了銷售，但美國政府正在對此進行打擊。如果它為 GLP-1 減肥藥物提供覆蓋，這隻前景看好的醫療保健股票可能會再次起飛。以僅 14 倍的市盈率，今天購買的諾和諾德股票在長期內可能會被證明是一個超值交易。</p>
</div><p>Eli Lilly is down 3% this year, and while it hasn't been in free fall like Novo Nordisk, it also looks like it may be a bit of an underrated buy. The stock trades at close to 50 times earnings, but future growth and larger profit margins could bring that multiple down significantly in the years ahead.</p>
<div class="lb-trans"><p>禮來今年下跌了 3%，雖然它沒有像諾和諾德那樣自由下跌，但看起來也可能是一個被低估的買入機會。該股票的市盈率接近 50 倍，但未來的增長和更大的利潤率可能會在未來幾年顯著降低這一倍數。</p>
</div>

以下是諾和諾德公司和禮來公司為什麼在今天仍可能是被嚴重低估的股票的原因